What's Happening?
ProMIS Neurosciences has announced positive interim results from its Phase 1b trial of PMN310, a treatment for early Alzheimer's disease. The trial, known as PRECISE-AD, showed no cases of amyloid-related imaging abnormalities-edema (ARIA-E) among participants,
including those with the APOE4 genotype. The study also observed early declines in biomarkers plasma pTau217 and CSF MTBR-tau243. The trial aims to evaluate the safety and efficacy of PMN310, which targets toxic amyloid-beta oligomers while avoiding plaque, potentially offering a safer and more effective treatment option. The company expects to report 12-month topline results in early 2027.
Why It's Important?
The interim results from the PRECISE-AD trial are significant as they suggest that PMN310 may offer a safer alternative to existing amyloid-targeting therapies, which are often associated with ARIA. By selectively targeting toxic oligomers, PMN310 could provide a more effective treatment for Alzheimer's disease with fewer side effects. The trial's positive safety profile and early biomarker changes support the potential of PMN310 to improve cognitive outcomes for patients with early Alzheimer's. ProMIS Neurosciences' focus on targeting misfolded proteins in neurodegenerative diseases highlights the importance of innovative approaches in addressing these complex conditions.
What's Next?
ProMIS Neurosciences plans to complete the 12-month dosing of all trial participants by the end of 2026, with unblinded topline results expected in the first quarter of 2027. These results will include cognitive outcomes and an expanded biomarker panel, providing further insights into the efficacy of PMN310. The company is also advancing other programs targeting misfolded proteins in diseases like ALS and Parkinson's, with ongoing IND-enabling studies.
Beyond the Headlines
The development of PMN310 underscores the potential of targeting specific protein misfolding mechanisms in neurodegenerative diseases. By focusing on toxic oligomers rather than plaque, ProMIS Neurosciences aims to address the underlying pathology of Alzheimer's disease more effectively. This approach could lead to a new class of therapies that offer improved safety and efficacy profiles, ultimately transforming the treatment landscape for Alzheimer's and other neurodegenerative disorders.
